Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of endometrial carcinoma, including any of the following cellular types:

- Mixed Mullerian carcinoma

- Serous carcinoma

- Clear cell carcinoma

- Primary advanced (FIGO stage III or stage IV) or metastatic recurrent disease

- Disease not curable by surgery

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with
x-ray, physical exam, or non-spiral CT scan OR ≥ 10 mm with spiral CT scan or MRI

- No known cerebral metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 12 weeks

- Platelet count ≥ 100,000/mm^3

- ANC ≥ 1,500/mm^3

- Hemoglobin ≥ 10 g/dL

- Creatinine ≤ 1.25 times upper limit of normal (ULN)

- Bilirubin ≤ 1.25 times ULN

- AST/ALT < 3 times ULN

- Glomerular filtration rate ≥ 50 mL/min

- LVEF ≥ 50% by ECHO

- Fertile patients must use effective contraception

- No myocardial infarction within the past 6 months

- No NYHA class II-IV congestive heart failure

- No third degree or complete heart block unless a pacemaker is in place

- No other malignancy within the past 5 years

- No concomitant medical illness (e.g., uncontrolled infection, uncontrolled angina, or
other relevant illness) that makes the prescribed treatments within this study
unfeasible

- No known hypersensitivity to study drugs

- No psychological, familial, sociological, or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy for disease recurrence

- At least 12 months since prior adjuvant therapy containing anthracyclines with
cumulative doses not exceeding the following:

- Epirubicin 600 mg/m²

- Doxorubicin 300 mg/m²

- At least 6 months since prior adjuvant therapy containing platinum

- At least 4 weeks since completion of radiotherapy involving the whole pelvis

- No concurrent radiotherapy or planned radiotherapy after study

- No concurrent endocrine, immunological, or other anticancer therapy

- No concurrent participation in another investigational drug study